Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom

Sponsor
AstraZeneca
Study ID
NCT04667312
Status
Completed

Conditions

  • Non-Small Cell Lung Cancer NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable Stage III non-small cell lung cancer receiving durvalumab in the United Kingdom (the CODAK study). Physicians who have treated patients who have locally advanced, unresectable Stage III NSCLC with durvalumab will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients receiving durvalumab through the Early Access Programme (EAP) or post-reimbursement.

Key Dates

Start date
Jun 24, 2021
Status verified
Sep 2023
Primary completion
Sep 28, 2022
Completion
Sep 28, 2022

Study Design

Enrollment
115 participants (actual)

Primary Outcome Measure

Overall Survival [ Time Frame: 12 months ]

Related Studies